Abstract
The extracellular matrix (ECM) is a dynamic microenvironment and a major contributor to the adverse ventricular remodelling that follows myocardial infarction (MI), via activation of both direct pro-fibrotic pathways and matrix metalloproteinases (MMPs) that enhance collagenase activity. Reactive fibrosis, i.e. deposition of ECM materials remote from the region of the MI is clearly detrimental to ventricular function and contributory to adverse outcomes post- MI. Therefore, reversal of this process represents an important therapeutic target in post-MI management and treatment of established heart failure. A number of existing agents exert their beneficial effects in part via reductions in ECM deposition. Furthermore, specific anti-fibrotic drugs have been developed and are currently being explored for these and other cardiac conditions where pathological ECM deposition is felt to be contributory to disease progression.
Keywords: fibrosis, remodelling, renin-angiotensin, endothelin, transforming growth factor, collagen
Current Pharmaceutical Design
Title: Fibrosis as a Therapeutic Target Post-Myocardial Infarction
Volume: 11 Issue: 4
Author(s): Fiona See, Andrew Kompa, Jennifer Martin, Dion A. Lewis and Henry Krum
Affiliation:
Keywords: fibrosis, remodelling, renin-angiotensin, endothelin, transforming growth factor, collagen
Abstract: The extracellular matrix (ECM) is a dynamic microenvironment and a major contributor to the adverse ventricular remodelling that follows myocardial infarction (MI), via activation of both direct pro-fibrotic pathways and matrix metalloproteinases (MMPs) that enhance collagenase activity. Reactive fibrosis, i.e. deposition of ECM materials remote from the region of the MI is clearly detrimental to ventricular function and contributory to adverse outcomes post- MI. Therefore, reversal of this process represents an important therapeutic target in post-MI management and treatment of established heart failure. A number of existing agents exert their beneficial effects in part via reductions in ECM deposition. Furthermore, specific anti-fibrotic drugs have been developed and are currently being explored for these and other cardiac conditions where pathological ECM deposition is felt to be contributory to disease progression.
Export Options
About this article
Cite this article as:
See Fiona, Kompa Andrew, Martin Jennifer, Lewis A. Dion and Krum Henry, Fibrosis as a Therapeutic Target Post-Myocardial Infarction, Current Pharmaceutical Design 2005; 11 (4) . https://dx.doi.org/10.2174/1381612053382098
DOI https://dx.doi.org/10.2174/1381612053382098 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fatty Acids - Induced Lipotoxicity and Inflammation
Current Drug Metabolism Pleiotropic Effects of Rimonabant: Clinical Implications
Current Pharmaceutical Design Pharmacological Regulators of Intracellular Calcium Release Channels
Current Pharmaceutical Design Bariatric Surgery and it Effects on the Respiratory System
Current Respiratory Medicine Reviews Review and Research on Feature Selection Methods from NMR Data in Biological Fluids. Presentation of an Original Ensemble Method Applied to Atherosclerosis Field
Current Drug Metabolism Acyl Thiourea Derivatives Containing Pyrazole Ring Selective Targeting of Human Aurora Kinases in Breast and Bone Cancer
Letters in Drug Design & Discovery Obesity: The Metabolic Disease, Advances on Drug Discovery and Natural Product Research
Current Topics in Medicinal Chemistry Current Strategies and Drug Targets in the Management of Type 2 Diabetes Mellitus
Current Drug Targets Targeting Cardiac Mast Cells: Pharmacological Modulation of the Local Renin-Angiotensin System
Current Pharmaceutical Design A Decade of Targets and Patented Drugs for Chemotherapy of Chagas Disease
Recent Patents on Anti-Infective Drug Discovery Modulatory Effects of Peroxisome Proliferator-Activated Receptor-γ on CXCR3 Chemokines
Recent Patents on Inflammation & Allergy Drug Discovery General Anesthetics in Pediatric Anesthesia: Influences on the Developing Brain
Current Drug Targets Hepatocyte Growth Factor and Insulin-like Growth Factor-1 based Cellular Therapies for Oxidative Stress Injury
Current Stem Cell Research & Therapy Antiprotozoal Agents: An Overview
Anti-Infective Agents in Medicinal Chemistry Mesenchymal Stem Cells in Veterinary Regenerative Therapy: Basic Physiology and Clinical Applications
Current Stem Cell Research & Therapy Cellular and Molecular Mechanisms of Low Cardiac Output Syndrome after Pediatric Cardiac Surgery
Current Vascular Pharmacology Use of Diverse Chemometric and Validation Methods to Accurately Predict Human Urotensin-II Receptor Antagonist Activity
Current Computer-Aided Drug Design Retinoids: Impact on Adiposity, Lipids and Lipoprotein Metabolism
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Endogenous and Exogenous Ligands of Aryl Hydrocarbon Receptor: Current State of Art
Current Drug Metabolism Manual Thrombectomy During Primary Coronary Intervention in Acute Myocardial Infarction: A Brief Review
Reviews on Recent Clinical Trials